- Keryx Biopharmaceuticals (NASDAQ:KERX) announced that an interruption in the supply of Auryxia (ferric citrate) tablets is imminent due to a production-related issue converting active pharmaceutical ingredient to finished drug product.
- The company expects to make Auryxia available to patients when supply of Auryxia is back to adequate levels.
- The company expects to restore adequate supply of Auryxia and to make Auryxia available to patients during the fourth quarter of 2016.
- Keryx withdraws 2016 financial guidance due to the development.
- Shares of KERX are under a Nasdaq trading halt.
- Source: Press Release